Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease.
Iwasa M, Eguchi A, Tamai Y, Shigefuku R, Nakagawa R, Hasegawa H, Kondo J, Morikawa M, Miyoshi E, Nakagawa H. Iwasa M, et al. Among authors: nakagawa r, nakagawa h. Front Med (Lausanne). 2022 Aug 11;9:982128. doi: 10.3389/fmed.2022.982128. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36035413 Free PMC article.
Early prediction of COVID-19 severity using extracellular vesicle COPB2.
Fujita Y, Hoshina T, Matsuzaki J, Yoshioka Y, Kadota T, Hosaka Y, Fujimoto S, Kawamoto H, Watanabe N, Sawaki K, Sakamoto Y, Miyajima M, Lee K, Nakaharai K, Horino T, Nakagawa R, Araya J, Miyato M, Yoshida M, Kuwano K, Ochiya T. Fujita Y, et al. Among authors: nakagawa r. J Extracell Vesicles. 2021 Jun;10(8):e12092. doi: 10.1002/jev2.12092. Epub 2021 Jun 2. J Extracell Vesicles. 2021. PMID: 34122778 Free PMC article.
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience.
Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, Zhang J, Yumita S, Ishino T, Unozawa H, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Kanda T, Maruyama H, Mimura N, Kato J, Motohashi S, Kato N. Ogawa K, et al. Among authors: nakagawa m, nakagawa r. J Cancer. 2022 May 16;13(8):2656-2661. doi: 10.7150/jca.71494. eCollection 2022. J Cancer. 2022. PMID: 35711837 Free PMC article.
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Kobayashi K, et al. Among authors: nakagawa r. Liver Cancer. 2021 Dec 6;11(1):48-60. doi: 10.1159/000519868. eCollection 2022 Jan. Liver Cancer. 2021. PMID: 35222507 Free PMC article.
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus.
Ma Y, Nakamoto S, Ao J, Qiang N, Kogure T, Ogawa K, Nakagawa M, Fujiwara K, Iwanaga T, Kojima R, Kanzaki H, Koroki K, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Ogasawara S, Muroyama R, Chiba T, Kato J, Kato N. Ma Y, et al. Among authors: nakagawa m, nakagawa r. Int J Mol Sci. 2022 Oct 10;23(19):12015. doi: 10.3390/ijms231912015. Int J Mol Sci. 2022. PMID: 36233317 Free PMC article.
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells.
Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, Qiang N, Ma Y, Zhang J, Kogure T, Yumita S, Ishino T, Ogawa K, Kan M, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Nakamoto S, Muroyama R, Kato J, Kanda T, Maruyama H, Mimura N, Honda T, Murayama T, Nakamura H, Kato N. Iwanaga T, et al. Among authors: nakagawa m, nakagawa r. Biochem Biophys Res Commun. 2023 Jan 29;642:192-200. doi: 10.1016/j.bbrc.2022.12.025. Epub 2022 Dec 10. Biochem Biophys Res Commun. 2023. PMID: 36586187
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma.
Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Ao J, et al. Among authors: nakagawa r. J Cancer. 2021 Mar 5;12(9):2694-2701. doi: 10.7150/jca.56436. eCollection 2021. J Cancer. 2021. PMID: 33854629 Free PMC article.
[Development status of DAA against hepatitis C].
Kato N, Nakagawa R, Goto K, Muroyama R, Matsubara Y. Kato N, et al. Among authors: nakagawa r. Nihon Rinsho. 2015 Dec;73 Suppl 9:262-8. Nihon Rinsho. 2015. PMID: 26845942 Japanese. No abstract available.
553 results